This conference poster presents the validation of iPSC-derived cardiomyocytes (YBLiCardio) as a reliable in vitro model for evaluating cardiotoxicity during drug development. The cells demonstrated expression of key cardiac markers and functional electrophysiological properties, confirming their suitability for cardiac safety assessment.

The model was further evaluated using the Comprehensive in vitro Proarrhythmia Assay (CiPA) framework with a panel of reference compounds. YBLiCardio cells responded consistently with established CiPA data, enabling the identification of low, intermediate, and high proarrhythmic risk compounds. These findings highlight the potential of YBLiCardio cardiomyocytes as a powerful platform for cardiotoxicity evaluation, drug safety screening, and early-stage drug discovery.